Increased PTT Only: A Prolonged PTT with a Normal PT
Heparin in the specimen, which may be a result of heparin treatment of the patient
Treatment with low molecular weight heparin, argatroban, or lepirudin
A lupus anticoagulant (i.e., lupus inhibitor)
Deficiency of factor VIII (hemophilia A) or IX (hemophilia B)
Deficiency of factor VIII (mild or severe) associated with von Willebrand's disease
Deficiency of factor XI, XII, or prekallikrein (Fletcher factor)
An inhibitor to factor VIII or IX
Suggested Additional Lab Testing
If heparin contamination in the sample is a possibility, ask for a repeat PTT or, if necessary, get a heparin measurement.
To help differentiate between coagulation inhibitors and factor deficiencies, perform PTT mixing studies (patient plasma plus normal plasma in equal volumes).
A patient positive for the lupus anticoagulant should have at least one positive lupus anticoagulant screening test and at least one positive confirmatory test that involves detection of phospholipid neutralization by the lupus anticoagulant.
Factor assays for factors VIII, IX, XI XII, and, in rare circumstances, an assay for prekallikrein (Fletcher factor) can determine if a deficiency in one or more of these factors explains the prolonged PTT.
Bethesda Unit assay is used to quantitate the amount of antibody to factor VIII in a patient with a PTT mixing study result suggestive of a factor VIII inhibitor. An evaluation for von Willebrand includes factor VIII, von Willebrand factor, and ristocetin cofactor. The factor VIII in von Willebrand patients may not be low enough to prolong the PTT.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|